Advanced Search
Discover new calcs: choose 1 function + 1 more filter
Click here to discover
Pulmonary Embolism
calculators for
After you diagnose a PE, discover
Pulmonary Embolism
calculators for

    Calc Function

  • Calcs that help predict probability of a diseaseDiagnosis
  • Subcategory of 'Diagnosis' designed to be very sensitiveRule Out
  • Disease is diagnosed: prognosticate to guide treatmentPrognosis
  • Numerical inputs and outputsFormula
  • Med treatment and moreTreatment
  • Suggested protocolsAlgorithm





Chief Complaint


Organ System


Groupe d'Etude des Lymphomes Folliculaires (GELF) Criteria

Determines if immediate therapy for follicular lymphoma is required.


Refer to the staging systems FLIPI and Lugano classification to assist with risk stratifying patients. The GELF criteria is a quick test to determine which patients should be monitored versus treated now.


Treatment is varied depending on the stage and tumor burden.

Stages I-II

  • Treatment options include:
    • Involved field radiotherapy (IFRT)
    • Clinical trials
    • Active surveillance

Stages III-IV or Bulky Stage II – asymptomatic

  • Treatment options include:
    • Clinical trials
    • Active surveillance

Stages III-IV or Bulky Stage II – with GELF/BNLI risk factors or high-risk FLIPI score

  • Treatment options include:
    • Rituximab + cyclophosphamide, vincristine, doxorubicin, prednisone
    • Rituximab alone
    • Bendamustine + rituximab
    • Rituximab + cyclophosphamide, vincristine, prednisone
    • Clinical trials

Critical Actions

  • There is continued controversy around when and how to treat follicular lymphoma, including in patients with relapsed/refractory disease. Questions to consider when making treatment decisions:
    • When to initiate therapy versus active surveillance
    • Deciding amongst various treatment options
    • Balancing efficacy and toxicities of treatment options
    • Determining what constitutes a complete response/endpoint of treatment
  • Finally, with follicular lymphoma, a provider should be aware of transformation to diffuse large B-cell lymphoma, which is a more aggressive disease and would require prompt treatment.
Content Contributors